Please upgrade your browser.
Seattle Genetics, Inc. (SGEN) today announced the initiation of a phase Ib clinical trial evaluating SGN-75 in combination with everolimus (AfinitorÂ®) for patients with advanced metastatic renal cell carcinoma (RCC).
A cancer drug that isn't passing muster in clinical trials may still be the answer for some patients, a new study says.
A marker for diagnosis, prognosis and treatment
Join your friends from the Kidney Cancer Association for SU2C from Hollywood, September 7, 2012
The decades of research into the various molecular mechanistic pathways that cause the constellation of diseases known as âcancerâ have produced literally hundreds of new, exciting experimental medicines.
Children with kidney cancer were most at risk of developing diabetes, with 14.7 percent of those treated with radiation diagnosed with the condition by age 45, the study found.
Novartis, the Swiss pharmaceutical company, will appear before the Indian Supreme Court Wednesday to appeal against a patent rejection for a popular cancer drug. A decision in favor of the company could have a devastating impact on cheap supplies of many kinds of generic drugs for poor patients.
New Move Could Identify More Than 800,000 People With Hepatitis C
Computers may give new life to old medicines
Cellceutix Corp announced that it has entered into an agreement with Beth Israel Deaconess Medical Center, a teaching hospital of Harvard Medical School, on a research project with Kevetrin.
|Powered by NeonCRM|